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Abstract
Background & Aims—Treatment of inflammatory bowel disease (IBD) would benefit from
specific targeting of therapeutics to the intestine. We developed a strategy for localized delivery of
the immunosuppressive cytokine IL27, which is actively synthesized in situ by the food-grade
bacterium Lactococcuslactis (LL-IL-27), and tested its ability to reduce colitis in mice.
Methods—The 2 genes encoding mouse IL27 were synthesized with optimal codon usage for L
lactis and joined with a linker; a signal sequence was added to allow for secretion of the product.
The construct was introduced into L lactis. Colitis was induced via transfer of CD4+CD45RBhi T
cells into Rag−/− mice to induce colitis; 7.5 weeks later, LL-IL-27 was administered to mice via
gavage. Intestinal tissues were collected and analyzed.
Results—LL-IL-27 administration protected mice from T-cell transfer-induced enterocolitis and
death. LL-IL-27 reduced disease activity scores, pathology features of large and small bowel, and
levels of inflammatory cytokines in colonic tissue. LL-IL-27 also reduced numbers of CD4+ and
IL17+ T cells in gut-associated lymphoid tissue. The effects of LL-IL-27 required production of
IL10 by the transferred T cells. LL-IL-27 was more effective than either LL-IL-10 or systemic
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administration of recombinant IL27 in reducing colitis in mice. LL-IL-27 also reduced colitis in
mice following administration of dextran sodium sulfate.
Conclusions—L lactis engineered to express IL27 (LL-IL-27) reduces colitis in mice, by
increasing production of IL10. Mucosal delivery of LL-IL-27 could be a more effective and safer
therapy for IBD.
Keywords
mouse model; Crohn’s Disease; ulcerative colitis; immune regulation
Introduction
Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a
significant public health problem in Western societies, affecting 1 in 1000 individuals, and is
characterized by chronic, nonspecific inflammation in the large and/or small intestine1. IBD
greatly predisposes to colorectal cancer, in that twenty percent of ulcerative colitis patients
will develop it unless the colon is surgically removed2. It is currently thought that IBD
represents an atypical inflammatory immune response to normal gut flora3, 4.
The existing treatments for IBD include anti-inflammatory drugs, immunosuppressive drugs,
and, in severe cases, partial or complete resection of the bowel. Use of therapeutics resulting
in total immunosuppression risks compromising protection against pathogens such as
viruses and bacteria. Selective delivery to the target organ would be desirable. IL-10, for
example, is an anti-inflammatory cytokine that has a protective role in both mouse5 and
human6 IBD; however, systemic IL-10 treatment has yielded rather disappointing results in
multicenter trials7, 8 most likely due to low final concentrations of IL-10 in the intestine.
IL-27, a pleiotropic cytokine belonging to the IL-12 family, is composed of IL-27p28 and
Epstein Barr virus–induced protein 3 (Ebi3)9. It is primarily expressed by antigen presenting
cells and signals through a heterodimeric receptor (IL-27R) that contains a unique IL-27Rα
(WSX-1, TCCR) subunit and a gp130 subunit, which is shared by several cytokine receptors
in the IL-6 family10.
IL-27 was initially described as an immune stimulator of TH1 responses9; however, recent
studies have identified mechanisms in which IL-27 has an immunosuppressive role11, 12
including its ability to antagonize TH17 development13–16, induce IL-10 production12, 16–18,
suppress IL-6–induced T cell proliferation13, and promote Treg generation19. Furthermore, a
therapeutic effect in experimental allergic encephalomyelitis15, collagen-induced arthritis20,
and colitis21 was observed following IL-27 administration, and in a genome-wide
association study, low expressing variants of the IL-27 gene were found to be associated
specifically with human early onset IBD22.
In this study, we investigated mucosal delivery of IL-27 using a well-described delivery
system that enables oral delivery of biopharmaceuticals to the gastrointestinal tract by
genetically engineered Lactococcus lactis (L. lactis)23–25. We show that LL-IL-27 has a
therapeutic benefit in T cell-dependent chronic enterocolitis suggesting it may offer a safer,
more effective treatment option for IBD patients.
Results
Genetically engineered L lactis express bioactive IL-27
Murine IL-27 was synthesized in L lactis by incorporating a linker between its two chains,
and using codons and a secretory signal sequence preferred by L lactis (LL-IL-27)
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(Supplementary Fig. 1). Culture supernatants of LL-IL-27 were analyzed by western blot,
showing that LL-IL-27 expressed the Ebi3 (Fig. 1A, left) and p28 (Fig. 1A, right) subunits
of IL-27 at the predicted molecular weight of the IL-27 hyperkine (48.2 kDa).
LL-IL-27 induced phosphorylation of STAT1 and STAT3 albeit to a lesser degree than
rmIL-27 at comparable concentrations (Fig. 1B). TH1 transcription regulator Tbet was
upregulated by LL-IL-27 stimulation of naïve CD4+ T cells (Fig. 1C). LL-IL-27 stimulated
both IL-10 protein secretion (Fig. 1D, left) and gene expression (Fig. 1D, right) to
comparable levels as rmIL-27 in CD4+ cells. Neutralizing rmIL-27 and LL-IL-27 with IL-27
antibodies resulted in similar inhibition levels in all functional assays (Supplementary Fig.
2), confirming that LL-IL-27’s bioactivity is mediated by IL-27.
We investigated LL-IL-27’s localization and ability to induce IL-10 in vivo. Healthy
C57BL/6 mice were administered serial gavages of LL-IL-27 and GI tract sections were
assayed. The majority of L lactis was found in the intestinal lumen (Supplementary Fig. 3A),
more than 80% of gavaged L lactis was recovered (Supplementary Fig. 3B), and increased
IL-10 levels were found in intestinal luminal contents of LL-IL-27-treated mice compared to
LL-control-treated mice (Supplementary Fig. 3C).
LL-IL-27 treatment improves survival in murine enterocolitis
Transferring CD4+CD45RBhi T cells from healthy wildtype mice into Rag−/− mice induces a
diffuse enterocolitis at 5–8 weeks following T cell transfer26. Gavages of BM9 media23
(untreated), LL-control or LL-IL-27 were begun 7.5 weeks following naïve T cell transfer
and continued for 2 weeks. By week 8 post-transfer, untreated and LL-control-treated mice
began to die or had to be euthanized due to extent of disease, and by 10.5 weeks, all had
succumbed to disease. In contrast, LL-IL-27-treated mice were protected from death (Fig.
2A). A disease activity index (DAI) was used that reflects several parameters of IBD27. LL-
IL-27-treated mice did not show occult/gross blood in stool, stool consistency was nearly
normal, whereas weight loss was partially relieved, thus contributing to a decreased DAI
(Fig. 2B). Histopathological analysis of distal colons demonstrated that LL-IL-27-treated
mice had normal morphology, while untreated and LL-control-treated mice had extensive
inflammatory infiltration and goblet cell loss (Fig. 2C). LL-IL-27-treated mice also had less
pathology in the small intestine compared to untreated and LL-control-treated mice (Fig.
2D).
To verify whether treatment with LL-IL-27 had a negative consequence on intestinal barrier
function, we used the limulus amoebocyte lysate (LAL) assay to measure LPS in the plasma.
Our analysis showed comparable LPS levels among healthy, untreated, LL-control-, and LL-
IL-27-treated mice indicating an intact intestinal barrier (Supplementary Fig. 4). We also
tested whether LL-IL-27 increased susceptibility to the intestinal pathogen Citrobacter
rodentium. LL-control- and LL-IL-27-treated mice had similar body weights
(Supplementary Fig. 5A) as untreated mice, but had lower CFU in fecal material, colon,
spleen (Supplementary Fig. 5B), and liver (Supplementary Fig. 5B), demonstrating that LL-
IL-27 does not exacerbate infection by an enteric pathogen.
To determine if LL-IL-27 was effective in a different mouse model of colitis, independent of
T cells, acute colitis induced by dextran sulfate sodium (DSS) was evaluated. Although LL-
IL-27 treatment did not protect from weight loss (Supplementary Fig. 6A), stool consistency
was normal (Supplementary Fig. 6B) and there was no occult/gross blood in the stool
(Supplementary Fig. 6C), resulting in a lower DAI (Supplementary Fig. 6D).
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LL-IL-27 is more effective than systemic IL-27 treatment in T cell induced colitis
To compare LL-IL-27 with systemically administered IL-27 protein, recombinant mouse
(rm) IL-27 was injected intraperitoneally for five days and compared with LL-IL-27 by
gavage. Although LL-IL-27 treatment over five days was somewhat less effective than a two
week treatment, it reduced the DAI by about half (Fig. 3A) and eliminated microscopic
lesions (Fig. 3B). By comparison, systemic rmIL-27 had no therapeutic effect (Fig. 3A and
B). Following rmIL-27 treatment, IL-27 was readily detectable in plasma and induced
circulating IL-10 (Fig. 3C); however, IL-10 levels in the distal colon were lower compared
to mice receiving LL-IL-27 (Fig. 3D). In healthy mice, LL-IL-27 did not induce higher
IL-10 levels than rmIL-27 in any tissue analyzed(Supplementary Fig. 7).
LL-IL-27 reduces inflammatory cytokines and increases IL-10 in vivo
To address the protective mechanism of LL-IL-27, gene expression for inflammatory
cytokines and transcription factors was quantified in distal colons (Fig. 4A). Reductions in
gene expression for IL-1α, IL-6, IFN-γ, and IL-23 were seen in the LL-IL-27-treated group
relative to the LL-control-treated group. IL-17A, IL-17F, and RORγt, all of which are
markers of TH17 cells, were also reduced. Tbet, Foxp3, and TGF-β gene expression was not
affected.
IL-10 is required to establish and maintain immune tolerance towards enteric bacteria as
shown by studies in which mice with a targeted disruption of the IL-10 gene develop
spontaneous enterocolitis5, 28. The IL-10 pathway is also implicated in IBD based on GWAS
studies29, 30. Because some effects of IL-27 act via IL-1012, 17, 18, we investigated the role
of LL-IL-27-induced IL-10 in T cell transfer enterocolitis. LL-IL-27 induced higher IL-10
protein (Fig. 4B, top) and transcript (Fig. 4B, bottom) levels than untreated or LL-control-
treated mice.
IL-10 can be produced by a variety of immune cells including lymphocytes and
macrophages; therefore, we investigated which cell type produced IL-10. C57BL/6 mice and
Rag−/− mice were given serial gavages of LL-IL-27 for 2 days. There was an increase in
IL-10 protein levels (Fig. 4C, top) and gene expression (Fig. 4C, bottom) in distal colons of
LL-IL-27-treated C57BL/6 mice compared to the untreated C57BL/6 control. However,
there were no detectable levels of IL-10 in the LL-IL-27-treated Rag−/− mice, thus, LL-
IL-27-induced IL-10 in the T cell transfer model was dependent on T cells and presumably
derives from T cells themselves. We also treated macrophages with LPS and varying
concentrations of rmIL-27 to determine if macrophages were a source of IL-10. We did not
observe a difference in IL-10 induction between LPS-only and LPS with rmIL-27
(Supplementary Fig. 8); therefore it is unlikely that macrophages were the source of LL-
IL-27 induced IL-10 in vivo. We next sought to identify the IL-10-producing T cell
population. Healthy IL-10 reporter mice were treated with serial inoculations of LL-IL-27
for 2 days. Increased reporter expression was observed in CD8+ and CD4+CD8α+(double
positive, DP) from Peyer’s patches of LL -IL-27-treated mice compared to untreated mice
(Fig. 4D).
IL-10 is required for LL-IL-27’s therapeutic effect, but LL-IL-10 is ineffective
To assess whether IL-10 induction was required for LL-IL-27’s therapeutic effect, we
transferred CD4+CD45Rbhi T cells from IL-10−/− mice to Rag−/− mice, and treated them
with LL-IL-27 once enterocolitis was established. All mice had succumbed to disease by
10.5 weeks following transfer; therefore IL-10 is required for LL-IL-IL-27’s therapeutic
effect (Fig. 5A). Steidler et al. demonstrated that LL-IL-10 alleviates DSS colitis and the
onset of colitis in IL-10−/− mice23. Since LL-IL-27’s therapeutic efficacy depended on
IL-10, we investigated whether LL-IL-10 was as effective as LL-IL-27 in treating T cell
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transfer enterocolitis. LL-IL-10-treated mice began to die or had to be euthanized by 8
weeks and by week 13, all had succumbed (Fig. 5A). LL-IL-10 also had a higher DAI than
LL-IL-27 (Supplementary Fig. 9). Microscopically, the gut had extensive pathology in both
the LL-IL-27-treated IL-10−/−CD4+CD45Rbhi T cell transferred mice and the LL-IL-10-
treated mice (Fig. 5b, left), whereas LL-IL-27-treatment lowered the histopathological score
(Fig. 5b, right). IL-10 levels in GI tissues and MLN were lower in LL-IL-10-treated mice
compared to LL-IL-27-treated mice (Fig. 5c). We also assessed IL-10 induction by a 10-fold
lower dose of LL-IL-27 (LD) and found that it was still able to induce higher levels of IL-10
compared to LL-IL-10 (Fig. 5c), although it did not lower the DAI as the normal dose of
LL-IL-27 (ND) did (Supplementary Fig. 9). Therefore, although IL-10 is required for LL-
IL-27’s therapeutic effect, LL-IL-27 is much more effective than LL-IL-10, at least in part
due to LL-IL-27’s ability to induce higher levels of IL-10.
LL-IL-27 decreases CD4+ and IL-17+ small intestinal IELs
IELs play an important role in suppressing enterocolitis in the T cell transfer model,
potentially by polarizing CD4+ cells toward a regulatory phenotype31, thus we investigated
the effect of LL-IL-27 treatment of mice with enterocolitis on T cell subsets in the
intraepithelium. Decreased percentages (Fig. 6A, top) and total cell number (Fig. 6B, left) of
CD4+ T cells and increased CD4+CD8α+ T cells (DP) in LL-IL-27-treated mice were
observed compared to untreated and LL-control-treated mice (Fig. 6A). Additionally, LL-
IL-27-treated mice had a lower CD4/CD8 ratio than untreated mice (Fig. 6B, right). In
contrast to colitic mice, this effect on T cell subsets was not observed in healthy mice that
received serial gavages of LL-IL-27 (Supplementary Fig. 10). Healthy mice showed no
effect of LL-IL-27 on Foxp3, the regulatory T cell CXCR3/Tbet32, CD25, CD44, CD62L, or
CD69 expression. In colitic mice, IL-10 mRNA was analyzed in each T cell subset and we
found that LL-IL-27 increased levels in the DP subset compared to LL-control (Fig. 6C). No
effects of LL-IL-27 were found on IFN-γ, Tbet, GATA-3, Foxp3, or PD-L1 mRNA in any T
cell subset (data not shown). To compare the effects of LL-IL-10 and rmIL-27 treatment
with LL-IL-27 on T cell phenotype, mice were treated for 7 days with LL-IL-27, LL-IL-10,
or rmIL-27. LL-IL-27 treatment increased CD8+ and DP frequency (Supplementary Fig.
11A) and total cell number (Supplementary Fig. 11B) and decreased CD4+ frequency in SI
IEL, MLN, and the spleen compared to LL-IL-10 and rmIL-27; however, the number of
CD4+ cells was not decreased by LL-IL-27 as seen after 14 days of treatment (Fig. 6A, top).
Foxp3 and Tbet/CXCR3 was not affected by 7 days of treatment (data not shown).
TH17 cells are involved in driving the onset and the development of IBD in mouse models33
and in patients34. Recently, IL-27 treatment was shown to decrease IL-17A-expressing cells
in a mouse model of colitis21, thus we examined the effect of LL-IL-27 treatment of mice
with colitis on TH17 cells using IL-17A/F dual-color reporter mice. LL-IL-27-treated mice
had decreased percentages (Fig. 6A, bottom) and total number (Fig. 6D) of IL-17A, IL-17F,
and IL-17A/F expressing cells compared to untreated and LL-control-treated mice.
Following LL-IL-27 treatment, decreased percentages of phagocytic cells were observed
(Supplementary Fig. 12). LL-IL-27 treatment decreased Gr1+CD11b+CD11c− cell
(predominately granulocytes) frequency in MLNs and colon lamina propria (LP)
(Supplementary Fig. 12A) and Gr1−CD11b+CD11c− cell (predominately monocytes)
frequency decreased in the spleen, MLNs, and cLP (Supplementary Fig. 12B).
In addition to inhibiting TH17 cells, IL-27 can control inflammation by promoting
development of IL-10-producing Tr1 regulatory cells17. We investigated the expression of
Tr1-associated genes in intestinal lymphocytes of LL-IL-27-treated mice. We did not find
any differences in ICOS, IL-21, or IL-21R between LL-control and LL-IL-27-treated mice
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(Supplementary Fig. 13). We did observe an increase in IL-27R gene expression in LL-
IL-27-treated mice.
Discussion
A localized delivery of the immunosuppressive cytokine, IL-27, was developed using L.
lactis to treat T cell-dependent chronic enterocolitis and T cell-independent acute colitis. In
the T cell transfer model of enterocolitis, LL-IL-27 improved survival, lessened colon and
small intestine pathology, and decreased inflammatory cytokine gene expression in the
colon. The therapeutic effect of LL-IL-27 was found to be dependent on T cell-derived
IL-10 production. LL-IL-27 decreased CD4+ and IL-17+ colitogenic T cells in the intestinal
intraepithelium. LL-IL-27 treatment improved DAI in the T cell-independent acute model of
colitis induced by DSS. By comparison to mucosal delivery, systemic rmIL-27 treatment
increased IL-10 levels in the circulation but not in the distal colon, which may contribute to
its failure to decrease disease activity and colon pathology. LL-IL-27 treatment was not
associated with any pathology, it did not affect intestinal barrier function, nor did it
exacerbate an intestinal infection caused by C. rodentium. Genetically modified L. lactis
have been shown to be safe in clinical trials (ClinicalTrials.gov identifiers NCT00729872
and NCT00938080). Therefore, LL-IL-27 is potentially a more effective and safer treatment
of IBD than current treatment options.
Standard therapy for IBD involves lifelong treatment of immunosuppressive agents
administered systemically, often with surgical resection of sections of bowel. Inefficient
drug delivery and intolerable side effects, particularly from manipulating cytokines, such as
TNF-α35 has contributed to limited treatment options for IBD patients. The indispensable
role of the anti-inflammatory cytokine, IL-10, in the regulation of mucosal immunity is most
aptly demonstrated by the development of spontaneous enterocolitis in IL-10−/− mice5 and
the occurrence of genetic variants of IL-10 in IBD patients29, 36. Clinical trials in which IBD
patients were given systemic recombinant IL-10, however, did not display clinical benefit,
possibly due to the low intestinal bioavailability and dose-limiting side effects8, 37. Delivery
of IL-10 locally by LL-IL-10 had shown promise by alleviating colitis in IL-10−/− mice and
mice exposed to DSS23, however it was shown to be much less effective than LL-IL-27 in
the T cell-induced colitis described in the present study. In our study, following LL-IL-27
treatment, IL-10 levels were elevated locally throughout the intestinal tract. In healthy mice,
serial gavages of LL-IL-27 induced IL-10 levels in the GI tract nearly 20 times greater than
the level delivered by LL-IL-1023 and further, LL-IL-27-treated mice had enhanced
survival, decreased disease activity, and improved mucosal healing of the colon to a greater
degree than LL-IL-10. Even at a 10-fold lower dose, LL-IL-27 induced higher levels of
IL-10 than LL-IL-10 in the areas of the GI tract. This may explain why LL-IL-27, despite
acting via IL-10, was a better therapeutic than LL-IL-10.
LL-IL-27 reduced the percentage of CD4+ T cells in the intraepithelium of the small
intestine and increased the percentage of DP cells. IL-10 mRNA was increased in the DP
subset of LL-IL-27-treated mice, and following serial gavages of healthy IL-10 reporter
mice, the DP subset of T cells was the highest IL-10 producer. Extrathymic DP cells,
specifically CD4+CD8αα+CD8β−TCRαβ+ cells, have been described as a unique cell type
localizing in the intestinal intraepithelial layer. These DP have been attributed a regulatory
function in inhibiting Th1-induced intestinal inflammation, primarily through the production
of IL-1038. They were also reported to express TGF-β, IFN-γ, and no IL-2, IL-4, or TNF-α.
We found that CD4+CD8αα+CD8β−TCRαβ+ cells make up the majority of the DP
population in healthy and colitic mice as previously reported38; however we did not observe
an LL-IL-27 effect on any of the cytokines that contribute to this cell population’s
regulatory function other than increased IL-10. Whether this DP population is able to
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regulate expansion of colitogenic CD4+ will require further investigation. Our
characterization of the DP cell type is similar to the findings of Kamanaka et al., in which
anti-CD3 treatment induced T regulatory cell 1 (Tr1)-like cells in SI intraepithelium39.
Briefly, transferred CD4+ cells into immunodeficient mice gained CD8+ expression in the SI
IEL compartment, and these cells expressed IL-10, but not Foxp3, IL-2, IL-4, and IFN-γ.
Our data suggest that the transferred naïve CD4+ T cells travel to the SI intraepithelium, and
following a 14-day dosing regimen of LL-IL-27, the CD4+ T cells gain CD8 expression,
either directly via IL-27 or secondary to IL-10 induction, then produce high levels of IL-10
that contribute to the efficacy of LL-IL-27 treatment for enterocolitis. While IL-10 is not
required for the CD4+CD8αα+CD8β−TCRαβ+ phenotype, it is critical for their function38.
Interestingly, T cell phenotype differed greatly between mice treated with LL-IL-27 for 7
days (Supplementary Fig. 11A) and 14 days (Fig. 6A, top). At some point after 7 days of
treatment, the number of CD4+ cells decreased markedly.
Currently, the role of IL-27 and its receptors in IBD has been interpreted differently based
on different models. Several studies have shown a pro-inflammatory role for IL-27 in
experimental colitis40–43, while others have shown anti-inflammatory effects44, 45. Two
studies have reported that IL-27Rα−/− CD4+CD45Rbhi T cells are unable to induce
colitis40, 46. Cox et al. concluded that the inability to induce colitis in Balb/c mice was due
to the increase of Foxp3+ cells converted from the naïve donor cells and low expansion of
IL-27Rα−/− donor cells in the large intestine40, while Kim et al. found that the inability to
induce colitis in C57Bl/6 mice was due to activated IL-27Rα−/− donor cells being unable to
survive, particularly in the large intestine, despite normal Foxp3 expression46. In our model,
mucosal delivery of IL-27 has an anti-inflammatory effect once enterocolitis is established,
possibly through the conversion of CD4+ effector cells to IL-10 producing-DP cells, and
without increasing Foxp3 expression. We did not observe an increase in CD4+ cells when
healthy mice were treated with LL-IL-27 (Supplementary Figure 10), nor did any signs of
colitis develop following a 30-day treatment of LL-IL-27 to healthy mice (data not shown);
therefore, our findings suggest that mucosal delivery of IL-27 has an anti-inflammatory
effect in T cell-dependent colitis. Consistent with our findings that IL-27 has therapeutic
efficacy, a GWAS study implicated a single nucleotide polymorphisms in the IL-27
regulatory region that reduces expression and increases susceptibility to IBD22.
In designing therapeutics for IBD patients, a balance is sought to inhibit enough immunity to
reduce IBD symptoms without rendering the patient systemically immunocompromised.
These results suggest that mucosal delivery of LL-IL-27 is potentially a more effective and
safer treatment of IBD in humans.
Methods
Induction of enterocolitis by T cell transfer, LL administration
The T cell transfer model was used to induce enterocolitis as reported in Ostanin et al.47.
Male Rag−/− were used for recipients, while female C57BL/6, IL-10−/−, or IL-17A/F dual
reporter mice were used for donors (see Supplementary Methods for details). Enterocolitis
was induced 7–7.5 weeks following cell transfer. We determined that the onset of
enterocolitis occurred when mice lost ≥5% body weight and had pasty, semi formed stools.
For experiments where C57BL/6 or IL-10−/− mice were cell donors, L. lactis administration
began following enterocolitis induction and continued with 14 daily gavages (5 days/week).
Tissues were either harvested immediately following death (Untreated, LL-control) or at 1
or 7 days post-gavage (LL-IL-27). For experiments where IL-17A/F dual-reporter mice were
cell donors, L. lactis administration began at 4 weeks and continued with 14 daily gavages.
Tissues were harvested 8 weeks following cell transfer. C57BL/6 and Rag−/− mice not
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receiving a T cell transfer were serially gavaged every half hour for five hours on day 1 and
one gavage on day 2. Tissues were harvested an hour after gavage.
Systemic treatment with rmIL-27
Seven weeks following T cell transfer, Rag−/− mice were injected intraperitoneally daily for
5 days with PBS, 500 ng or 1 μg murine rmIL-27 (R & D Systems). Mice were euthanized
three days after the final injection and their colons were processed for histopathology
analysis.
Histological analysis
Tissues (small and large intestine) from mice were fixed in 10% neutral-buffered formalin,
embedded in paraffin, sectioned, and stained with hematoxylin and eosin. H&E tissue
sections were evaluated and graded in coded fashion by a veterinary pathologist (M.R.A.).
See Supplementary Methods for scoring criteria.
Statistics
Statistical analysis was performed using the GraphPad Prism software (version 5.00;
GraphPad, San Diego, CA). Data are expressed as ± s.e.m. The Student two-tailed unpaired,
parametric t test was used to assess statistical differences between two experimental groups.
Asterisks indicate statistical differences, * P ≤ .05, ** P ≤ .01, *** P ≤ .005.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Genetically engineered L. lactis express active IL-27. (A) Ebi3 (left) and IL-27 p28 (right)
protein were detected in supernatants of LL-IL-27 by western blot. Murine CD4+ T cells
were stimulated with anti-CD3/CD28 in the presence of LL-IL-27 or rmIL-27. Bioactivity of
LL-IL-27 was confirmed through (B) phosphorylation of STAT1/3, (C) induction of Tbet
mRNA expression, and (D) increased IL-10 protein and gene expression measured by
ELISA and RT-PCR, respectively. Data representative of three independent experiments.
Data represents mean ± s.e.m. **P ≤ .01, *** P ≤ .005, determined by two-tailed Student’s t
test.
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LL-IL-27 improves survival in T cell transfer induced enterocolitis. CD4+CD45Rbhi T cells
from C57BL/6 mice were transferred to Rag−/− mice. Following onset of enterocolitis
around 7.5 weeks, mice were gavaged with BM9 media (untreated, UT), LL-control, or LL-
IL-27 for 14 days (shown by hatched bar). (A) Percent survival following T cell transfer
(n=5, data representative of three independent experiments), (B) Clinical disease activity
index (DAI) was determined at time of death (UT, LL-control) or 7 days after the last
gavage (LL-IL-27). (C) Representative H&E-stained sections of distal colons (top). Scale
bar (top row) = 100 μm, (bottom row) = 25 μm. Histopathological scores were determined
for the distal colon (bottom). (D) Representative H&E-stained sections of small intestines
(SI) (duodenum=duo, jejunum=jej, ileum=ile) (top). Scale bar = 100 μm. Histopathological
scores were determined for each section of the SI (bottom). Data represents mean ± s.e.m.
*P ≤ .05, ***P ≤ .005, determined by two-tailed Student’s t test.
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Systemic rmIL-27 treatment does not improve disease activity. CD4+CD45RbhiT cells were
transferred to Rag−/− mice. Following the onset of enterocolitis at 7.5 weeks, mice were
gavaged with LL-IL-27 or were intraperitoneally injected with rmIL-27 for 5 consecutive
days. Tissues were harvested three days following the last treatment. (A) Clinical disease
activity index (DAI) was determined at day of harvest. (B) Histopathological scores were
determined for the distal colon. (C) Plasma was analyzed for IL-27 and IL-10. (D) Tissue
homogenates were analyzed for IL-10. Duo: duodenum, Jej: jejunum, Ile: Ileum, PC:
proximal colon, DC: distal colon. (n=3–5, data representative of two independent
experiments) Data represents mean ± s.e.m. *P ≤ .05, *** P ≤ .005, determined by two -
tailed Student’s t test.
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LL -IL-27 decreases inflammatory cytokines, increases IL-10 in vivo. (A) Gene expression
in distal colons of healthy C57BL/6 mice and mice with enterocolitis treated with LL-
control or LL-IL-27 was determined by RT-PCR. (B) Rag−/− mice with enterocolitis were
untreated (UT) or treated with LL-control or LL-IL-27 for 14 days. Colons were harvested 7
days following the last gavage or at death. (C) Healthy C57BL/6 and Rag−/− mice were
serially gavaged with LL-IL-27 every half hour for 5 hours on Day 1 and one gavage on Day
2. Colons were harvested 1 hour following the last gavage. Untreated C57BL/6 and Rag−/−
mice were used as controls. Top, IL-10 protein levels in distal colon homogenate were
determined by ELISA. Bottom, IL-10 gene expression in whole distal colons was semi-
quantitated by RT-PCR. Levels were normalized to HPRT. (D) LL-IL-27 increases IL-10
expression in DP and CD8 cells. Healthy Vert-X IL-10/eGFP mice were treated with 3 serial
gavages on Day 1 and one gavage on Day 2 of BM9 media (UT) or LL-IL-27. Mice were
euthanized and small intestines were harvested an hour following the last gavage. IL-10
expression was analyzed on CD3+ lymphocytes from Peyer’s Patches. DN: CD4−CD8−
cells, DP: CD4+CD8α+ cells. (n=4, data representative of three independent experiments).
Data represents mean ± s.e.m. *P ≤ .05 **P ≤ .01, ***P ≤ .005, determined by two -tailed
Student’s t test. NS=no significance.
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IL-10 is necessary for LL-IL-27’s therapeutic effect. CD4+CD45Rbhi T cells from C57BL/6
mice or IL-10−/− mice were transferred to Rag−/− mice. Following the onset of enterocolitis
at 7.5 weeks, mice were gavaged with LL-IL-27 or LL-IL-10 for 14 days. Colons were
harvested upon death (UT and LL-control) or the day after the last gavage (LL-IL-27). (A)
Percent survival following T cell transfer (B) Representative H&E-stained sections of distal
colons (left). Scale bar = 100 μm. Histopathological scores were determined for the distal
colon (right) (C) Tissue homogenates were analyzed for IL-10 in mice gavaged with LL-
IL-27 at the normal dose (ND) or at a 10-fold lower dose (LD), or LL-IL-10. Duo:
duodenum, Jej: jejunum, Ile: Ileum, PC: proximal colon, DC: distal colon. (n=3–5, data
representative of three independent experiments). Data represents mean ± s.e.m. *P ≤ .05,
**P ≤ .01, determined by two-tailed Student’s t test.
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LL -IL-27 treatment decreases CD4+ and IL-17+ small intestinal intraepithelial
lymphocytes. CD45Rbhi T cells from C57BL/6 mice or IL-17A/F dual-color reporter mice
were transferred to Rag−/− mice to induce enterocolitis. Rag−/− mice with enterocolitis were
treated with LL-control or LL-IL-27 for 14 days. Organs were harvested upon death (UT
and LL-control) or the day after the last gavage (LL-IL-27). C57BL/6 mice were used as
healthy controls. Lymphocytes were isolated from the small intestine intraepithelium and
were pooled from 2 mice. (A) Representative dot plot analysis of CD4+ and CD8α+ cells
(top) and IL-17A and IL-17F cells (bottom). Numbers in dot plot quadrants indicate percent
of CD3+ cells. Average total cells and CD4 single positive (CD4+), CD8α single positive
(CD8 +), and CD4+CD8α+ (double-positive, DP) cells (B, left), CD4/CD8α ratio (B, right),
and IL-17A, IL-17F, and IL-17A/F double-expressor cells (C). T cell subset numbers were
calculated from the total cell count multiplied by the percentage of T lymphocytes obtained
from flow cytometric analyses. (D) IL-10 gene expression was semi-quantitated for CD4+,
CD8α+ and DP purified populations. DP: CD4+CD8α+ cells. (n=3, data representative of
two independent experiments). Data represents mean ± s.e.m. *P ≤ .05 ** P ≤ .01
determined by two -tailed Student’s t test.
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